The positive ratio of both RPL6 and cyclin E was 70% (38 of 55 patients) while the negative ratio (including specimens that did not stain) of both RPL6 and cyclin E was 11% (6 of 55 patients) in human gastric cancer specimens. Here, RPL6 is linked to gastric cancer.